Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,657 Cr
verified against source
Revenue YoY
11.4%
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Fortis Healthcare reported a steady Q1 FY24 with consolidated revenue of INR 1,657 crore, up 11.4% YoY, driven by hospital revenue growth of 13.6% to INR 1,354 crore. However, consolidated EBITDA margin contracted 40bps to 16.5% due to lower occupancy (64% vs 65%) and unfavorable payer mix skewed toward government schemes. Hospital EBITDA margin stood at 15.2%, impacted by seasonal softness and higher employee costs from annual increments and new clinical hires. Diagnostics revenue grew 2% to INR 342 crore, with non-COVID revenue up 9% and EBITDA margin improving to 19.4%. Management maintained guidance for hospital margins to reach 18-20% and ARPOB growth of 4-5% for FY24. Key strategic actions include the planned IPO of Agilus Diagnostics and acquisition of a 350-bed hospital in Manesar. Risk: Nursing staff attrition and wage inflation could pressure margins.
Colored figures show movement against the previous available record.
Guidance to track
- Management reiterated guidance for hospital EBITDA margins to trend towards 18-20% in coming quarters, despite Q1 margin of 15.2%.
- Management expects ARPOB to grow 4-5% for the full year, moderating from Q1's 12% growth due to base effects.
- Management expects occupancy to reach 70% over the medium term, supported by bed additions and ramp-up.
- Planned bed additions of 300-400 per year, primarily brownfield expansions in NCR, Mulund, and Kolkata.
Risks flagged
- Management acknowledged industry-wide nursing shortage and wage inflation, which could pressure margins.
- Q1 occupancy at 64% and higher government scheme mix impacted profitability; recovery depends on mix improvement.
- Oncology growth (34% YoY) comes with lower margins due to revenue sharing, potentially dragging overall hospital margins.
- New bed additions and the Manesar acquisition may face delays in commissioning or occupancy ramp-up.
Key quotes
- We are maintaining that guidance in full. As Dr. Raghuvanshi said, it is a good start in terms of revenue. Profitability is slightly on the lower side, but we expect to pick up the pace in the forthcoming quarters.
- Nursing is a challenge for the entire industry, and this challenge remains. ... We will see this kind of stress for next 3 to 4 years going forward as well.
- We can easily target 1% at least on the staff cost over a period of 2 years.
Research modules